Clinical Trials | May 23, 2026
Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial
Clears major obesity endpoints at 80 weeks
Clears major obesity endpoints at 80 weeks
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Transition to a fermentation-based globally integrated CDMO platform
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations
Pharma veteran with over three decades of industry experience to lead Alembic’s animal health growth and market expansion initiatives.
Subscribe To Our Newsletter & Stay Updated
